Genetic and pathogenic characteristics of SARS-CoV-2 variants

doi:10.11958/20220509

Abstract

Abstract:

Coronavirus disease 2019 (COVID-19) can evolve rapidly via genetic mutation. At present, SARS-CoV-2 variants have been categorized as of concern variants (B.1.1.7, B.1.351, P.1, B.1.617.2 and B.1.1.529), variants of interest (B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, B.1.617.1, C.37 and B.1.621) and variants under monitoring. These variants have had a significant impact on with significant impact on transmissibility of virus, morbidity, reinfection and mortality in the population. Compared to other variants, Omicron new variant has characteristics such as strong infectivity, immune escape, causing a high risk of infection surges. This review outlines genetic characteristics of SARS-CoV-2 variants, the epidemiological, gene mutation and clinical characteristics of new variant Omicron of SARS-CoV-2, the collection method and detective method of SARS-CoV-2 specimen, vaccination and treatment for COVID-19, in order to provide guidance for the prevention and treatment of SARS-CoV-2.

Key words: SARS virus, genetic variation, mutation, virulence, SARS-CoV-2, Omicron

CLC Number:

R373.1

Figures/Tables 4

References 31

[1]	KOELLE K, MARTIN M A, ANTIA R, et al. The changing epidemiology of SARS-CoV-2[J]. Science, 2022, 375(6585):1116-1121. doi: 10.1126/science.abm4915.
[2]	World Health Organization. COVID-19 Weekly Epidemiological Update[EB/OL]. (2022-05-03)[2022-05-03]. https://covid19.who.int/.
[3]	KARIM S S A, KARIM Q A. Omicron SARS-CoV-2 variant:a new chapter in the COVID-19 pandemic[J]. Lancet, 2021, 398(10317):2126-2128. doi: 10.1016/S0140-6736(21)02758-6.
[4]	MOGHADDAR M, RADMAN R, MACREADIE I. Severity,pathogenicity and transmissibility of delta and lambda variants of SARS-CoV-2,toxicity of spike protein and possibilities for future prevention of COVID-19[J]. Microorganisms, 2021, 9(10):2167. doi: 10.3390/microorganisms9102167.
[5]	KE Z, OTON J, QU K, et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions[J]. Nature, 2020, 588(7838):498-502. doi: 10.1038/s41586-020-2665-2.
[6]	ESSALMANI R, JAIN J, SUSAN-RESIGA D, et al. Distinctive roles of furin and TMPRSS2 in SARS-CoV-2 infectivity[J]. J Virol, 2022, 96(8):e0012822. doi: 10.1128/jvi.00128-22.
[7]	CHOI J Y, SMITH D M. SARS-CoV-2 variants of concern[J]. Yonsei Med J, 2021, 62(11):961-968. doi: 10.3349/ymj.2021.62.11.961.
[8]	CHAVDA V P, PATEL A B, VAGHASIYA D D. SARS-CoV-2 variants and vulnerability at the global level[J]. J Med Virol, 2022, 94(7):2986-3005. doi: 10.1002/jmv.27717.
[9]	THAKUR S, SASI S, PILLAI S G, et al. SARS-CoV-2 mutations and their impact on diagnostics,therapeutics and vaccines[J]. Front Med (Lausanne), 2022, 9:815389. doi: 10.3389/fmed.2022.815389.
[10]	TATSI E B, FILIPPATOS F, MICHOS A. SARS-CoV-2 variants and effectiveness of vaccines:a review of current evidence[J]. Epidemiol Infect, 2021, 149:e237. doi: 10.1017/S0950268821002430.
[11]	UK Health Security Agency. Deltacron:a new variant that combines Omicron and Delta discovered in Cyprus 4 UPDATES[EB/OL]. (2022-01-08)[2022-05-03]. https://www.coronaheadsup.com/coronavirus/deltacron-a-new-variant-that-combines-omicron-and-delta-discovered-in-cyprus/.
[12]	KREIER F. Deltacron:the story of the variant that wasn't[J]. Nature, 2022, 602(7895):19. doi: 10.1038/d41586-022-00149-9.
[13]	VAUGHAN A. Omicron emerges[J]. New Sci, 2021, 252(3363):7. doi: 10.1016/S0262-4079(21)02140-0.
[14]	中国青年网. 天津从入境人员中检出奥密克戎变异株为中国内地首例[EB/OL]. (2021-12-13)[2022-04-03].
	China Youth Net. Tianjin detected the Omicron variant of COVID-19 in a person who traveled from overseas, first in Chinese mainland[EB/OL]. (2021-12-13)[2022-04-03]. http://news.youth.cn/jsxw/202112/t20211213_13350683.htm.
[15]	KHANDIA R, SINGHAL S, ALQAHTANI T, et al. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant,salient features,high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic[J]. Environ Res, 2022, 209:112816. doi: 10.1016/j.envres.2022.112816.
[16]	NYBERG T, FERGUSON N M, NASH S G, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 Omicron (B.1.1.529) and delta (B.1.617.2) variants in England:Acohort study[J]. Lancet, 2022, 399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7.
[17]	JOHN E L Y. Brit battled Covid for a record 505 days before dying in the longest known case of infection, scientists reveal[EB/OL]. (2022-04-22)[2021-05-05]. https://www.dailymail.co.uk/health/article-10738903/Worlds-longest-known-Covid-infection-went-505-DAYS-scientists-reveal.html.
[18]	GHOSH N, NANDI S, SAHA I. A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein[J]. Int Immunopharmacol, 2022, 105:108565. doi: 10.1016/j.intimp.2022.108565.
[19]	BHATTACHARYA M, SHARMA A R, DHAMA K, et al. Omicron variant (B.1.1.529) of SARS-CoV-2:understanding mutations in the genome,S-glycoprotein,and antibody-binding regions[J]. Geroscience, 2022, 44(2):619-637. doi: 10.1007/s11357-022-00532-4.
[20]	OU J, LAN W, WU X, et al. Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events[J]. Signal Transduct Target Ther, 2022, 7(1):138. doi: 10.1038/s41392-022-00992-2.
[21]	CAMERONI E, BOWEN J E, ROSEN L E, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift[J]. Nature, 2022, 602(7898):664-670. doi: 10.1038/s41586-021-04386-2.
[22]	MENNI C, VALDES A M, POLIDORI L, et al. Symptom prevalence,duration,and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of Omicron and Delta variant dominance:Aprospective observational study from the ZOE COVID Study[J]. Lancet, 2022, 399(10335):1618-1624. doi: 10.1016/S0140-6736(22)00327-0.
[23]	MASLO C, FRIEDLAND R, TOUBKIN M, et al. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared with previous waves[J]. JAMA, 2022, 327(6):583-584. doi: 10.1001/jama.2021.24868.
[24]	王玉亮, 王峰, 耿洁. 细胞因子与细胞因子风暴[J]. 天津医药, 2020, 48(6):494-499.
	WANG Y L, WANG F, GENG J. Cytokine and cytokine storm[J]. Tianjin Med J, 2020, 48(6):494-499. doi: 10.11958/20200323.
[25]	UK Health Security Agency. UK:XE may have a growth rate -10% greater than Omicron BA.2 1 UPDATE[EB/OL]. (2022-03-26)[2022-04-05]. https://www.coronaheadsup.com/science/.variants/recombinants/uk-deltacron-xe-may-have-a-growth-rate-10-greater-than-omicron-ba-2/.
[26]	Yonhap News Agency. (4th LD) S. Korea's new COVID-19 cases bounce back to more than 200,000[EB/OL].(2022-04-12)[2022-04-26]. https://en.yna.co.kr/view/AEN20220412001354320?section=search.
[27]	WANG Y, CHEN X, WANG F, et al. Value of anal swabs for SARS-COV-2 detection:a literature review[J]. Int J Med Sci, 2021, 18(11):2389-2393. doi: 10.7150/ijms.59382.
[28]	YOO H M, KIM I H, KIM S. Nucleic acid testing of SARS-CoV-2[J]. Int J Mol Sci, 2021, 22(11): 6150. doi: 10.3390/ijms22116150.
[29]	BRÜMMER L E, KATZENSCHLAGER S, GAEDDERT M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2:A living systematic review and meta-analysis[J]. PLoS Med, 2021, 18(8):e1003735. doi: 10.1371/journal.pmed.1003735.
[30]	GUEVARA-HOYER K, FUENTES-ANTRÁS J, DE LA FUENTE-MUÑOZ E, et al. Serological tests in the detection of SARS-CoV-2 antibodies[J]. Diagnostics (Basel), 2021, 11(4):678. doi: 10.3390/diagnostics11040678.
[31]	Update to living WHO guideline on drugs for covid-19[J]. BMJ, 2022, 377:o1005. doi: 10.1136/bmj.o1005.

VOC	首次报告	S蛋白基因突变位点
		S1			S2
		受体结合区域（RBD）	N-端区域（NTD）	其他	S2
B.1.1.7（Alpha）	2020.09英国	N501Y	Δ69~70、Δ144~145	A570D、D614G、P681H	T716l、S982A、D1118H
B.1.351（Beta）	2020.05南非	K417N、E484K、N501Y	D80A、D215G、Δ242~244	D614G	A701V
P.1（Gamma）	2020.11巴西	K417T、E484K、N501Y	L18F、T20N、P26S、 D138Y、R190S	D614G、H655Y	T1027l、V1176F
B.1.617.2（Delta）	2020.10印度	L452R、T478K	T19R、E156G、Δ157~158	D614G、P681R	D950N
B.1.1.529 （Omicron）	2021.11 博茨瓦纳	G339D、S371L、S373P、S375F、K417N、 N440K、G446S、S477N、T478K、E484A、 Q493R、G496S、Q498R、N501Y、Y505H	A67V、Δ69~70、T95I、 G142D、Δ143-145、 Δ211、L212I、ins214EPE	T547K、D614G、H655Y、 N679K、P681H	N764K、D796Y、 N856K、Q954H、 N969K、L981F
VOC	影响
VOC	传播力		致病性	免疫逃逸能力
B.1.1.7 （Alpha）	比原始毒株高43%~82%		致死率比原始毒株高64%	恢复期患者的血清中和活性约降低至原来的1/4;疫苗接种者的血清中和活性约降低至原来的1/3
B.1.351 （Beta）	比原始毒株高约50%		院内致死风险比已报道毒株高31%	恢复期患者的血浆中和活性降低至原来的1/34~1/12;疫苗接种者的血清中和活性降低至原来的1/9.5~1/4.4
P.1 （Gamma）	是原始毒株的1.7~2.4倍		对20~49岁女性的致死率升高	恢复期患者的血浆中和活性降低至原来的1/14~1/7.5;疫苗接种者的血清中和活性降低至原来的1/3.8~1/3.2
B.1.617.2 （Delta）	比原始毒株高97%,比Alpha 变异株高40%~50%		危重症率高于原始毒株;致死率比原始毒株高133%	恢复期患者及疫苗接种者的血清中和活性均有所降低
B.1.1.529 （Omicron）	为Delta变异株的3~6倍		相对较低	恢复期患者血清的中和敏感性降低,但仍有一定的保护作用;既往感染过其他变异株且未接种疫苗患者的血清不能中和Omicron变种

VOC	首次报告	S蛋白基因突变位点
		S1			S2
		受体结合区域（RBD）	N-端区域（NTD）	其他	S2
B.1.1.7（Alpha）	2020.09英国	N501Y	Δ69~70、Δ144~145	A570D、D614G、P681H	T716l、S982A、D1118H
B.1.351（Beta）	2020.05南非	K417N、E484K、N501Y	D80A、D215G、Δ242~244	D614G	A701V
P.1（Gamma）	2020.11巴西	K417T、E484K、N501Y	L18F、T20N、P26S、 D138Y、R190S	D614G、H655Y	T1027l、V1176F
B.1.617.2（Delta）	2020.10印度	L452R、T478K	T19R、E156G、Δ157~158	D614G、P681R	D950N
B.1.1.529 （Omicron）	2021.11 博茨瓦纳	G339D、S371L、S373P、S375F、K417N、 N440K、G446S、S477N、T478K、E484A、 Q493R、G496S、Q498R、N501Y、Y505H	A67V、Δ69~70、T95I、 G142D、Δ143-145、 Δ211、L212I、ins214EPE	T547K、D614G、H655Y、 N679K、P681H	N764K、D796Y、 N856K、Q954H、 N969K、L981F
VOC	影响
VOC	传播力		致病性	免疫逃逸能力
B.1.1.7 （Alpha）	比原始毒株高43%~82%		致死率比原始毒株高64%	恢复期患者的血清中和活性约降低至原来的1/4;疫苗接种者的血清中和活性约降低至原来的1/3
B.1.351 （Beta）	比原始毒株高约50%		院内致死风险比已报道毒株高31%	恢复期患者的血浆中和活性降低至原来的1/34~1/12;疫苗接种者的血清中和活性降低至原来的1/9.5~1/4.4
P.1 （Gamma）	是原始毒株的1.7~2.4倍		对20~49岁女性的致死率升高	恢复期患者的血浆中和活性降低至原来的1/14~1/7.5;疫苗接种者的血清中和活性降低至原来的1/3.8~1/3.2
B.1.617.2 （Delta）	比原始毒株高97%,比Alpha 变异株高40%~50%		危重症率高于原始毒株;致死率比原始毒株高133%	恢复期患者及疫苗接种者的血清中和活性均有所降低
B.1.1.529 （Omicron）	为Delta变异株的3~6倍		相对较低	恢复期患者血清的中和敏感性降低,但仍有一定的保护作用;既往感染过其他变异株且未接种疫苗患者的血清不能中和Omicron变种